Resources
Resources
Controlled resources about Vanguard Biotech Systems and NextGenAMR, drawn only from approved content. Each item answers a real question for a specific audience.
How to describe VBS and NextGenAMR
A precise-language guide for journalists, partners and analysts: the approved way to describe Vanguard Biotech Systems and NextGenAMR, and the descriptions to avoid.
- For:
- press, partners, procurement, investors
- Version:
- 1.0.0
- Updated:
- 2026-07-24
Company and product
Vanguard Biotech Systems (VBS) is the company; NextGenAMR is its first product. Present VBS as the entity and NextGenAMR as a product of VBS — not the other way round.
Describe NextGenAMR as a bioinformatics platform for antimicrobial-resistance evidence from whole-genome sequencing (WGS) data, currently in a controlled preview and under validation, within a published scope.
Please do not describe it as
Do not present NextGenAMR as an autonomous diagnostic system, as a tool that selects or recommends treatment, or as a replacement for phenotypic antimicrobial susceptibility testing (AST). It supports professional interpretation; it does not replace it.
Avoid absolute performance or time-saving claims. VBS does not publish performance metrics while validation is ongoing.
Corporate boilerplate & company facts
The approved corporate boilerplate and basic company facts, ready to quote accurately.
- For:
- press, investors, partners
- Version:
- 1.0.0
- Updated:
- 2026-07-24
Boilerplate
Vanguard Biotech Systems (VBS) is a biotechnology company developing NextGenAMR, a bioinformatics platform that organises antimicrobial-resistance evidence from whole-genome sequencing data for professional interpretation. NextGenAMR is in a controlled preview and under validation, within a published scope.
Company facts
Founder & CEO: Juan Manuel Gómez Vargas. Operational location: Granada, Spain. First product: NextGenAMR. For registered corporate identification, see the legal notice.
Further technical documents
Additional technical documents (technical overview, genotype vs phenotype, provenance, abstention, WGS data preparation, validation summary, data-flow) are prepared and released only after competent scientific review. They are not published until then.